White prescription pill bottle beside thyroid tablets and a recall notice

Vitruvias Therapeutics Recalls One Lot of Thyroid Tablets in the United States After Tests Found the 30 Mg Medicine Could Be Superpotent


WASHINGTON, DC — Vitruvias Therapeutics Inc. is voluntarily recalling one lot of thyroid tablets, USP 30 mg, after testing found the medicine may be stronger than intended. The company said the tablets could be “superpotent,” which means they may deliver more thyroid hormone than expected.

The recalled lot is number 504950. Vitruvias said the tablets were distributed from Jan. 31 through Sept. 30, 2025, and carry an expiration date of Sept. 30, 2026.

Health Risks Noted

The company said taking superpotent thyroid tablets can lead to hyperthyroidism, or an overactive thyroid, along with related negative health effects. Vitruvias said older adults, pregnant women and infants are the groups most at risk from being overtreated for hypothyroidism.

Vitruvias also said it has not received reports of adverse events tied to the recall so far. The recall applies to a single lot of the 30 mg tablets, not to all thyroid medication made by the company.

How The Recall Emerged

Vitruvias said testing confirmed the product had the potential to be stronger than it should be. The company then moved ahead with the voluntary recall of the affected lot. No illness reports had been linked to the tablets at the time of the announcement.

The notice does not say how many bottles or tablets were included in the lot. It also does not identify where the recalled product was sold beyond the distribution dates listed by the company.

What Patients Should Do

Vitruvias said people currently taking the recalled medication should not stop using it without first contacting their healthcare provider for guidance or a replacement prescription. Patients can check their bottles for lot number 504950 and compare the expiration date with the company’s notice.

The recall was issued by Vitruvias Therapeutics Inc. People who have questions about the affected tablets can look to the company’s recall notice or contact their healthcare provider for next steps. No adverse-event reports had been received when the recall was announced.

More on health, care, money and the people nearby, on Westlake Arrow.